Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Fate Therapeutics Stock News

FATENASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

Fate Therapeutics (FATE) Forecast

News

Earnings Fate Therapeutics (FATE) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest Fate Therapeutics Stock News | NASDAQ:FATE | Benzinga

Get the latest news on Fate Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Fate Therapeutics performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, March 06, 2025

Stifel Maintains Hold on Fate Therapeutics, L...
Benzinga Newsdesk
Wedbush Reiterates Neutral on Fate Therapeuti...
Benzinga Newsdesk
Wells Fargo Maintains Equal-Weight on Fate Th...
Benzinga Newsdesk
Needham Reiterates Hold on Fate Therapeuticst...
Benzinga Newsdesk

Wednesday, March 05, 2025

Fate Therapeutics Q4 2024 GAAP EPS $(0.44) Mi...
Benzinga Newsdesk

Monday, December 09, 2024

Fate Therapeutics shares are trading higher a...
Benzinga Newsdesk
Fate Therapeutics Unveils Phase 1 Data For FT...
Benzinga Newsdesk

Friday, November 29, 2024

Fate Therapeutics Announces Leadership Transi...
Benzinga Newsdesk

Wednesday, November 27, 2024

Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor

Tuesday, November 19, 2024

Needham Reiterates Hold on Fate Therapeutics
Benzinga Newsdesk

Monday, November 18, 2024

Fate Therapeutics Shares Halted On Circuit Br...
Benzinga Newsdesk
Fate Therapeutics shares are trading higher a...
Benzinga Newsdesk
Fate Therapeutics Presents 6-Month Follow-Up ...
Benzinga Newsdesk

Wednesday, November 13, 2024

Needham Reiterates Hold on Fate Therapeutics
Benzinga Newsdesk

Tuesday, November 12, 2024

Fate Therapeutics Q3 EPS $(0.40) Beats $(0.42...
Benzinga Newsdesk

Monday, November 11, 2024

Reported Saturday, Fate Therapeutics Showcase...
Benzinga Newsdesk

Thursday, August 22, 2024

HC Wainwright & Co. Reiterates Neutral on Fat...
Benzinga Newsdesk

Wednesday, August 14, 2024

Needham Reiterates Hold on Fate Therapeutics
Benzinga Newsdesk

Tuesday, August 13, 2024

Fate Therapeutics Q2 2024 Adj EPS $(0.33) Bea...
Benzinga Newsdesk

Tuesday, July 16, 2024

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor

Wednesday, June 26, 2024

Fate Therapeutics shares are trading lower ga...
Benzinga Newsdesk

Monday, June 17, 2024

Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Benzinga Insights
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Avi Kapoor
Fate Therapeutics shares are trading higher a...
Benzinga Newsdesk
Piper Sandler Upgrades Fate Therapeutics to O...
Benzinga Newsdesk

Thursday, May 16, 2024

Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
HC Wainwright & Co. Maintains Neutral on Fate...
Benzinga Newsdesk

Friday, May 10, 2024

Canaccord Genuity Maintains Buy on Fate Thera...
Benzinga Newsdesk
BMO Capital Maintains Market Perform on Fate ...
Benzinga Newsdesk
Wedbush Maintains Neutral on Fate Therapeutic...
Benzinga Newsdesk
Piper Sandler Maintains Neutral on Fate Thera...
Benzinga Newsdesk

Thursday, May 09, 2024

Fate Therapeutics Q1 2024 GAAP EPS $(0.47), I...
Benzinga Newsdesk
Fate Therapeutics Treats First Lupus Patient ...
Benzinga Newsdesk

Monday, May 06, 2024

Forecasting The Future: 8 Analyst Projections For Fate Therapeutics
Benzinga Insights
Wedbush Reiterates Neutral on Fate Therapeuti...
Benzinga Newsdesk

Friday, May 03, 2024

Fate Therapeutics Announces Presentation Of F...
Benzinga Newsdesk

Tuesday, April 23, 2024

Wedbush Reiterates Neutral on Fate Therapeuti...
Benzinga Newsdesk

Monday, April 22, 2024

Fate Therapeutics To Present FT819 Proof-Of-C...
Benzinga Newsdesk

Thursday, April 11, 2024

Where Fate Therapeutics Stands With Analysts
Benzinga Insights
Needham Reiterates Hold on Fate Therapeutics
Benzinga Newsdesk

Wednesday, April 10, 2024

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights

Thursday, March 28, 2024

B of A Securities Maintains Underperform on F...
Benzinga Newsdesk

Tuesday, March 19, 2024

Fate Therapeutics Announces Pricing Of $100M ...
Benzinga Newsdesk
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
Benzinga Insights
HC Wainwright & Co. Reiterates Neutral on Fat...
Benzinga Newsdesk

Tuesday, February 27, 2024

Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
Benzinga Insights
Barclays Maintains Overweight on Fate Therape...
Benzinga Newsdesk
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
Wedbush Maintains Neutral on Fate Therapeutic...
Benzinga Newsdesk

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved